Hyponatremic acute heart failure
Hyponatremic acute heart failure (AHF) is a severe pathological condition with a poor prognosis and limited therapeutic options apart from fluid restriction. Hyponatremic AHF represents 20% of total acute heart failure patient population. In absence of effective treatments, most patients remain hyponatremic at discharge.
Chronically increased vasopressin plays a key role in the development of dilutional hyponatremia and AHF. Significant reduction of vasopressin is expected to normalize natremia and alleviate systemic congestion. This will translate into a decrease of hyponatremia-related disorders, length of patient hospitalization and subsequent risk of re-hospitalization and an improvement in quality of life.